#United States #Chicago #Genprex #Reqorsa #ASCO2025

Genprex to Present Clinical Trial Design for Reqorsa® Gene Therapy at ASCO 2025

Genprex, Inc., a pioneering clinical-stage gene therapy company, is preparing to present the design of its Acclaim-3 clinical trial at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. This conference is to be held from May 30 to June 3, 2025, in Chicago, Illinois, and online. The focus of this presentation will be on the innovative use of Reqorsa® Gene Therapy combined with Tecentriq® aimed at treating extensive stage small cell lung cancer (ES-SCLC).

In this era of transformative cancer therapies, Genprex stands at the forefront, working diligently to offer innovative and life-altering solutions for patients battling serious conditions such as cancer and diabetes. Ryan Confer, President and CEO of Genprex, expressed pride in the progress of the Acclaim-3 trial, highlighting the potential benefits of reintroducing the TUSC2 gene, a vital tumor suppressor that is diminished in 100% of SCLC cases. The urgency of this research is underscored by the current median progression-free survival (PFS) of only 2.6 months for patients receiving standard treatments.

The Acclaim-3 trial, set to evaluate the effectiveness of Reqorsa® in combination with AstraZeneca's Tecentriq, consists of a Phase 1/2 structure, focusing on the unique administration of the TUSC2 gene. Reqorsa® is delivered as a DNA plasmid encapsulated in a specialized lipoplex that enables targeted delivery into cancer cells, with hopes of restoring TUSC2 expression and enhancing patient outcomes.

The poster presentation will outline the trial's specific design details, including eligibility criteria, treatment regimen, and safety protocols. Eligible patients will have undergone 3-4 cycles of induction therapy without disease progression, making them prime candidates for the combination maintenance therapy. The study aims to evaluate efficacy and safety while closely monitoring adverse events and the expression levels of the TUSC2 protein in patients, using validated criteria for precision.

Moreover, the incorporation of Tecentriq alongside Reqorsa® could lead to enhanced tumor responsiveness, as previously seen in xenograft studies. These studies show noteworthy tumor cell destruction when both therapies are administered together, alongside improved immune cell infiltration and a reduction in myeloid-derived suppressor cells within the tumor environment.

Participants in the Phase 1 portion of the trial will be assigned to escalating dose cohorts of Reqorsa® administered every 21 days, in conjunction with Tecentriq, with careful assessment at each dose level to inform further escalation.

As interest in innovative cancer therapies grows, Genprex's work exemplifies the ongoing shift towards more effective and personalized treatment options. The outcome of the Acclaim-3 trial could pave the way for significant advancements in SCLC treatment and represents a commitment to extending patient survival and improving quality of life.

Following the presentation, a detailed copy of the findings will be made accessible on Genprex's official website. This step underscores Genprex's dedication to transparency and knowledge sharing within the oncology community.

In conclusion, Genprex is on a promising path to redefine treatment protocols for small cell lung cancer. With the backing of esteemed collaborators and a robust clinical framework, the Acclaim-3 trial emerges as a beacon of hope for patients facing this challenging diagnosis. Interested stakeholders and investors are invited to stay updated through Genprex's communication channels as the company continues its innovative journey.

About Genprex, Inc.

Genprex is dedicated to transforming the landscape of cancer and diabetes therapies through the development of groundbreaking gene therapies. By leveraging advanced technology and strategic collaborations, the company seeks to expand treatment possibilities for patients grappling with diseases that currently offer limited responsive solutions. With a focus on gene delivery via their proprietary Oncoprex® system, Genprex is positioning itself as a leader in the clinical development of effective therapies.

For further updates, interested parties are encouraged to follow Genprex on their social media platforms and subscribe to newsletters for timely news regarding progress and advancements in their clinical trials.